{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:22:56Z","timestamp":1788906176130,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,31]],"date-time":"2016-01-31T00:00:00Z","timestamp":1454198400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.6061\/clinics\/2016(01)08","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T12:34:48Z","timestamp":1454675688000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control"],"prefix":"10.1016","volume":"71","author":[{"given":"Carolina C R","family":"Bet\u00f4nico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M O","family":"Titan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L\u00facia C","family":"Correa-Giannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia","family":"Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.6061\/clinics\/2016(01)08_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc10-2377","article-title":"Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study","volume":"34","author":"Huang","year":"2011","journal-title":"Diabetes Care"},{"key":"10.6061\/clinics\/2016(01)08_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/640632","article-title":"Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic kidney disease in primary care setting in france: a cross-sectional study","volume":"2013","author":"Grandfils","year":"2013","journal-title":"Int J Endocrinol"},{"issue":"4","key":"10.6061\/clinics\/2016(01)08_bib3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0272-6386(89)80201-X","article-title":"Insulin resistance of uremia","volume":"14","author":"Hager","year":"1989","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.6061\/clinics\/2016(01)08_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1523-1755.1998.00898.x","article-title":"Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease","volume":"53","author":"Fliser","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ki.1982.132","article-title":"Insulin resistance in uremia mediated by postbinding defects","volume":"22","author":"Smith","year":"1982","journal-title":"Kidney Int"},{"issue":"4 Suppl 2","key":"10.6061\/clinics\/2016(01)08_bib6","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1681\/ASN.2005121343","article-title":"Renal protection in diabetes: role of glycemic control","volume":"17","author":"Fioretto","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.6061\/clinics\/2016(01)08_bib7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","author":"Foundation NK","year":"2012","journal-title":"Am J Kidney Dis. Elsevier Inc"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2016(01)08_bib8","first-page":"S14","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","author":"Classification","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000357680","article-title":"Novel hypoglycaemic agents: considerations in patients with chronic kidney disease","volume":"126","author":"Game","year":"2014","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.6061\/clinics\/2016(01)08_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7861\/clinmedicine.9-4-353","article-title":"Management of type 2 diabetes: NICE guidelines","volume":"9","author":"Sibal","year":"2009","journal-title":"Clin Med"},{"key":"10.6061\/clinics\/2016(01)08_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/151706","article-title":"Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting","volume":"2014","author":"Wu","year":"2014","journal-title":"Int J Nephrol"},{"issue":"6","key":"10.6061\/clinics\/2016(01)08_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/pds.3501","article-title":"Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world","volume":"22","author":"Kajbaf","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.6061\/clinics\/2016(01)08_bib14","first-page":"341","article-title":"How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study","volume":"10","author":"Penfornis","year":"2014","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2014.19","article-title":"Metformin and other antidiabetic agents in renal failure patients","volume":"87","author":"Lalau","year":"2015","journal-title":"Kidney Int"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4065\/mcp.2011.0010","article-title":"Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry","volume":"86","author":"Meadows","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"10.6061\/clinics\/2016(01)08_bib17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.6061\/clinics\/2016(01)08_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/210821","article-title":"Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin","volume":"2012","author":"Kim","year":"2012","journal-title":"Exp Diabetes Res"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2010.01.119","article-title":"Metformin induces suppression of NAD(P)H oxidase activity in podocytes","volume":"393","author":"Piwkowska","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0891-5849(94)90152-X","article-title":"DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria","volume":"16","author":"Ha","year":"1994","journal-title":"Free Radic Biol Med"},{"key":"10.6061\/clinics\/2016(01)08_bib21","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2012.13629","article-title":"Antidiabetic drugs and kidney disease\u2013recommendations of the Swiss Society for Endocrinology and Diabetology","volume":"142","author":"Zanchi","year":"2012","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib22","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic Kidney Disease: A Report From an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib23","first-page":"22","article-title":"Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure","volume":"12","author":"Sampanis","year":"2008","journal-title":"Hippokratia"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5414\/CNP60090","article-title":"Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure","volume":"60","author":"Inoue","year":"2003","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.6061\/clinics\/2016(01)08_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920011794520053","article-title":"Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice","volume":"12","author":"Abe","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.6061\/clinics\/2016(01)08_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.ajkd.2007.08.012","article-title":"Management of glycemia in patients with diabetes mellitus and CKD","volume":"50","author":"Lubowsky","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"2 Suppl 2","key":"10.6061\/clinics\/2016(01)08_bib28","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.ajkd.2013.10.049","article-title":"Glycemic management in ESRD and earlier stages of CKD","volume":"63","author":"Williams","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.6061\/clinics\/2016(01)08_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2125.2003.01785.x","article-title":"The pharmacokinetics of pioglitazone in patients with impaired renal function","volume":"55","author":"Budde","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.2007060678","article-title":"Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease","volume":"19","author":"Schneider","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.6061\/clinics\/2016(01)08_bib31","first-page":"161","article-title":"Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin","volume":"6","author":"Russo","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.6061\/clinics\/2016(01)08_bib32","first-page":"893","article-title":"A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment","volume":"7","author":"Eligar","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-014-0198-2","article-title":"Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.6061\/clinics\/2016(01)08_bib34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01382.x","article-title":"Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment","volume":"13","author":"Nowicki","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.6061\/clinics\/2016(01)08_bib35","first-page":"1","article-title":"Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease?: a pooled analysis of six phase III clinical trials","author":"von Eynatten","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"10.6061\/clinics\/2016(01)08_bib36","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2165\/11205080-000000000-00000","article-title":"Alogliptin: a review of its use in the management of type 2 diabetes mellitus","volume":"70","author":"Scott","year":"2010","journal-title":"Drugs"},{"issue":"18","key":"10.6061\/clinics\/2016(01)08_bib37","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.6061\/clinics\/2016(01)08_bib38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11936-014-0353-y","article-title":"Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect","volume":"16","author":"Standl","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"10.6061\/clinics\/2016(01)08_bib39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12020-014-0179-0","article-title":"Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature","volume":"46","author":"Giorda","year":"2014","journal-title":"Endocrine"},{"issue":"3","key":"10.6061\/clinics\/2016(01)08_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3810\/pgm.2013.05.2672","article-title":"Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors","volume":"125","author":"Freeman","year":"2013","journal-title":"Postgrad Med"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout","year":"2014","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.6061\/clinics\/2016(01)08_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00304849","article-title":"The renal metabolism of insulin","volume":"27","author":"Rabkin","year":"1984","journal-title":"Diabetologia"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1210\/edrv-2-2-210","article-title":"Insulin metabolism and degradation","volume":"2","author":"Duckworth","year":"1981","journal-title":"Endocr Rev"},{"issue":"3","key":"10.6061\/clinics\/2016(01)08_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1210\/edrv-9-3-319","article-title":"Insulin degradation: mechanisms, products, and significance","volume":"9","author":"Duckworth","year":"1988","journal-title":"Endocr Rev"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1463-1326.2007.00802.x","article-title":"Insulin therapy in renal disease","volume":"10","author":"Iglesias","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.6061\/clinics\/2016(01)08_bib46","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.metabol.2005.01.028","article-title":"Insulin resistance and postprandial triglyceride levels in primary renal disease","volume":"54","author":"Charlesworth","year":"2005","journal-title":"Metabolism"},{"issue":"8","key":"10.6061\/clinics\/2016(01)08_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1046\/j.1464-5491.2003.01025.x","article-title":"Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients","volume":"20","author":"Biesenbach","year":"2003","journal-title":"Diabet Med"},{"issue":"4","key":"10.6061\/clinics\/2016(01)08_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042018813501188","article-title":"Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin","volume":"4","author":"Kulozik","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"10.6061\/clinics\/2016(01)08_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.0894-0959.2004.17346.x","article-title":"Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease","volume":"17","author":"Snyder","year":"2004","journal-title":"Semin Dial"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200059020-00009","article-title":"Insulin glargine","volume":"59","author":"Gillies","year":"2000","journal-title":"Drugs"},{"issue":"04","key":"10.6061\/clinics\/2016(01)08_bib51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2155-6156.1000189","article-title":"Efficacy and Safety of Insulin Glargine in Type 2 Diabetic Patients with Renal Failure","volume":"03","author":"Niafar","year":"2012","journal-title":"J Diabetes Metab"},{"issue":"24","key":"10.6061\/clinics\/2016(01)08_bib52","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.2146\/ajhp060102","article-title":"Insulin detemir: a long-acting insulin product","volume":"63","author":"Jones","year":"2006","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib53","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2337\/dc07-0002","article-title":"Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study","volume":"30","author":"Porcellati","year":"2007","journal-title":"Diabetes Care"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40262-013-0113-2","article-title":"Insulin degludec: pharmacokinetics in patients with renal impairment","volume":"53","author":"Kiss","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl D","key":"10.6061\/clinics\/2016(01)08_bib55","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.clinthera.2007.12.013","article-title":"Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections","volume":"29","author":"Bode","year":"2007","journal-title":"Clin Ther"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib56","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2337\/diacare.26.2.502","article-title":"Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy","volume":"26","author":"Ruggenenti","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib57","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ndt\/gfi205","article-title":"Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus","volume":"21","author":"Ersoy","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib58","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5414\/CPP41492","article-title":"Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus","volume":"41","author":"Czock","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.jrn.2014.07.011","article-title":"Advantage of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal insufficiency","volume":"25","author":"Urata","year":"2015","journal-title":"J Ren Nutr"},{"issue":"5","key":"10.6061\/clinics\/2016(01)08_bib60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2005.02476.x","article-title":"Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment","volume":"60","author":"Holmes","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.6061\/clinics\/2016(01)08_bib61","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc12-0578","article-title":"A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency","volume":"35","author":"Baldwin","year":"2012","journal-title":"Diabetes Care"},{"issue":"3","key":"10.6061\/clinics\/2016(01)08_bib62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.ackd.2014.03.004","article-title":"Glycemic exposure, glycemic control, and metabolic karma in diabetic complications","volume":"21","author":"Thomas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.6061\/clinics\/2016(01)08_bib63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/intqhc\/mzr036","article-title":"Adherence to clinical practice guidelines and outcomes in diabetic patients","volume":"23","author":"Oh","year":"2011","journal-title":"Int J Qual Health Care"},{"issue":"7 Suppl","key":"10.6061\/clinics\/2016(01)08_bib64","first-page":"S195","article-title":"Improving treatment success rates for type 2 diabetes: recommendations for a changing environment","volume":"16","author":"Triplitt","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.6061\/clinics\/2016(01)08_bib65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"Bailey","year":"2014","journal-title":"BMC Res Notes"},{"issue":"5","key":"10.6061\/clinics\/2016(01)08_bib66","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2012.07.017","article-title":"Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline","volume":"60","author":"Slinin","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.6061\/clinics\/2016(01)08_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc12-2182","article-title":"Diabetes Care: “state of the union.”","volume":"36","author":"Cefalu","year":"2012","journal-title":"Diabetes Care"},{"issue":"12","key":"10.6061\/clinics\/2016(01)08_bib68","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2337\/dc12-0573","article-title":"Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"35","author":"Ramirez","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.6061\/clinics\/2016(01)08_bib69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sdi.12198","article-title":"Updates on the management of diabetes in dialysis patients","volume":"27","author":"Rhee","year":"2014","journal-title":"Semin Dial"},{"issue":"26","key":"10.6061\/clinics\/2016(01)08_bib70","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1056\/NEJMe1313104","article-title":"New therapies for diabetic kidney disease","volume":"369","author":"Himmelfarb","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222013011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222013011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:01:08Z","timestamp":1761721268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222013011"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_abstract&pid=S1807-59322016000100047&lng=en&nrm=iso","label":"SCIELO"},{"URL":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4732385\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1807593222013011"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2016(01)08","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2016(01)08","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}